12 projects
Status
Domain
Organization Type
CardioCube: COVID AI-driven conversational agent
CardioCube COVID enables virtual care for patients with coronavirus and quarantined individuals using AI-driven conversational agents deployed on smartphones and smart speakers. Automatic forward triage system allows to multiply healthcare provider's workforce increasing patients and providers safety thorough physical distancing. CardioCube COVID will include following modules: 1. Clinical Follow-Up - periodically, using mobile or voice interface, user answers a set of clinical questions to evaluate the health status at home. CardioCube red-flags patients/quarantined individuals at-r...
The new breathing therapy method based on short-term intermittent exposure to hypoxia in rehabili...
The current worldwide healthcare focus is on countering acute COVID-19 effects in emergency care patients. However, two distinct SARS-CoV-2 syndrome phases have been already identified: while the first acute phase is characterised by a prevalent respiratory syndrome, the second one which accompanies gradual respiratory syndrome recovery is marked by a prolonged bed rest syndrome and invasive mechanical ventilation sequelae. This means that following the acute infection stage, worldwide health services will have to cope with the significant secondary issue, namely large numbers of patients...
Cytokines as biomarkers and therapeutic targets in COVID-19 infection
Cytokines play an important role in the pathogenesis of COVID-19 infection. A subgroup of patients develops a cytokine storm syndrome, correlating with a bad clinical outcome. For example, the concentration of the inflammatory cytokine Interleukin-6 (IL-6) has been recognized as a risk factor for mortality and for respiratory failure in Chinese and German patient cohorts, respectively. Tocilizumab, an antibody directed against the IL-6 receptor alpha chain, is used in clinical trials as well as an FDA-approved inhibitor of Jaks, tyrosine kinases which mediate the signal transduction of mult...
Xcope - Corona-Home-Control
The project is to develop an app that allows people to communicate with quarantined doctors. So you don't have to leave home if you have symptoms of a coronavirus and don't infect other people. We are building a stethoscope for the smartphone so that they can auscultate their lungs and also send it to their doctor. If we have enough data, we can also build machine learning or deep learning models to automatically detect when the coronavirus is causing pneumonia (then it becomes dangerous). This allowed people to be treated at home and only go to a hospital if the disease worsened.
Communication4Care
In a nutshell: Communication4Care (Com4Care) is a cloud-based communication platform to facilitate GDPR conform interoperability and link of relevant (sensor) data with structured patient-related information. No data files need to be exchanged and the platform provides a secure data storage and (real time or asynchronous) communication channel. Thus, improved standardized data acquisition, process monitoring, and data interpretation are possible. The patient can collect and report individual findings and outcomes (PROMs) and 'distribution of information' or sending of data files (electronic...
OPEN LABEL RANDOMIZED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF PLASMA THERAPY FROM RECOVERE...
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated SARS-CoV-2, and the disease caused by this virus has been designated COVID-19. Currently there are no approved therapeutic agents available for coronaviruses. The purpose of this trial is to provide substantial evidence on the efficacy and safety of the treatment of selected COVID-19 patients with plasma obtained from convalescent COVID-19 patients ('PLASMA').
COVAMBU: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COV...
The purpose of this Multi-centre, adaptive, randomized trial is to provide substantial evidence on the efficacy, or lack of efficacy and safety of treatments available in Luxembourg, given to COVID-19 positive-testing-patients who do not yet require hospitalization. Efficacy will be assessed through virological response and clinical outcomes.
Innovative end-to-end solution for respiratory diseases detection and genotyping
Our innovative end-to-end solution for respiratory diseases detection and genotyping is composed of 3 main compoenets as follows: First, we want, through a multiplex qPCR assay, to target and differentiate in priority COVID-19, SARS, H5N1, H1N1 (devastating diseases) from seasonal flu (under control). Second, we propose to develop an NGS and SANGER assay for the following Intended uses: Respiratory diseases Genotyping, Screening, Monitoring, Quasispecies identification, Epidemiological studies. Third, we target to establish a large COVID-19 and SARS worldwide database , compare patient ...
